A Phase 1 interventional study of Teriflunomide HMR1726 and cholestyramine in Multiple Sclerosis, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-21.
Sponsored by Sanofi · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing teriflunomide in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. teriflunomide · Multiple Sclerosis.
Among the 22 studies testing teriflunomide in Multiple Sclerosis, this one is the 20th largest by enrollment, is one of 2 that started in 2014, is the only one in phase 1, and was the 16th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 22 studies testing teriflunomide in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
teriflunomide: first FDA approval 2012 (AUBAGIO), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2014.
This study's enrollment of 12 is below the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 138 across the 22 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
44 studies in Multiple Sclerosis by Sanofi: 3 open now, 6 under way, 4 of them phase 3. Of 38 finished, 23 (61%) have results posted.
Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 40th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 1, and was the 22nd registered.
Sanofi’s Multiple Sclerosis studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing teriflunomide in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 44 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of 14 mg administration in Chinese healthy subjects
Secondary Objective:
To assess the safety and tolerability after a single oral dose of 14 mg teriflunomide in Chinese healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female subjects, between 18 and 45 years of age, inclusive. Body weight between 50.0 and 95.0 kg, inclusive, if male, and between 45.0 and 85.0 kg, inclusive, if female, between 19.0 and 24.0 kg/m2, inclusive.
Certified as healthy by a comprehensive clinical assessment and lab test. Subject must use an appropriate method. Having given written prior to any procedure related to the study.
Exclusion criteria:
Blood donation, any volume, within 3 months before inclusion. Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure ≥20 mmHg within 3 minutes when changing from the supine to the standing position.
Excessive consumption of beverages with xanthine bases (>4 cups or glasses per day).
If female, pregnancy (defined as positive β-hCG blood test), breast-feeding. Any medication (including St John's Wort and traditional Chinese herb medicine) within 14 days before the inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, with the exception of hormonal or menopausal hormone replacement therapy; any vaccination within the last 28 days.
Any consumption of citrus (grapefruit, orange, etc) or their juices within 5 days before inclusion.
Subject (both male and female) who disagrees to use an appropriate contraception method .
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
Drug: Teriflunomide HMR1726 · Drug: cholestyramine
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:power Route of administration: oral
Pharmacokinetic parameters for teriflunomide determined from plasma concentration
Time frame: 5 weeks
safety assessments (adverse events, laboratory data, vital sign, and ECG parameters)
Time frame: 6 weeks
The record gives a start of May 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Teriflunomide · Cholestyramine Resin